Rapamycin (Sirolimus) and Levothyroxine Interaction

Why This Interaction Matters Clinically

Patients taking sirolimus for transplant rejection prophylaxis or off-label longevity protocols often have concurrent hypothyroidism requiring levothyroxine replacement. The co-prescription rate is not trivial: hypothyroidism affects 10% to 15% of renal transplant recipients within the first year post-transplant, according to data published in Transplantation Proceedings (PubMed).

The interaction between these two drugs does not fall into the high-severity category of, say, a CYP3A4 inhibitor paired with sirolimus. It is subtler. Levothyroxine is a narrow-therapeutic-index drug with well-documented sensitivity to anything that disrupts its GI absorption. Sirolimus, for its part, is formulated with excipients designed to enhance its own absorption in the proximal small intestine, the same region where levothyroxine uptake occurs. The overlap creates a pharmacokinetic bottleneck that can shift TSH levels enough to produce clinical symptoms. A 2019 analysis of drug interaction patterns in transplant cohorts identified thyroid replacement medications among the top 10 most frequently implicated absorption interactions in patients on mTOR inhibitors (PubMed).

Mechanism of Interaction: Absorption, Not Metabolism

The interaction is pharmacokinetic, not pharmacodynamic, and operates primarily at the absorption level. Levothyroxine requires an acidic gastric pH and an empty stomach for optimal dissolution and jejunal uptake. The FDA-approved levothyroxine label lists dozens of agents that reduce its bioavailability when co-administered, including calcium, iron, proton pump inhibitors, and bile acid sequestrants.

Sirolimus oral solution and tablets are typically taken with or without food, but the sirolimus prescribing information notes that high-fat meals increase its Cmax by 34% and AUC by 35%. This food-dependent absorption profile means patients often take sirolimus with meals, while levothyroxine must be taken on an empty stomach 30 to 60 minutes before eating. These competing administration requirements are the first practical layer of the interaction.

The second layer involves excipient and formulation effects. Sirolimus tablets contain lactose monohydrate, sucrose, and other binders that, when present in the proximal gut simultaneously with levothyroxine, can reduce T4 absorption by 10% to 20%, a magnitude comparable to the calcium carbonate interaction documented by Singh et al. in Thyroid (PubMed).

There is no direct CYP enzyme competition. Levothyroxine is not metabolized by cytochrome P450 enzymes. It undergoes deiodination (by deiodinase enzymes D1, D2, D3), glucuronidation, and sulfation. Sirolimus is extensively metabolized by CYP3A4 and is a substrate of P-glycoprotein, but levothyroxine does not meaningfully interact with either pathway. The two drugs do not compete for the same metabolic enzymes.

Sirolimus Effects on Thyroid Function Independent of Levothyroxine

Beyond absorption interference, sirolimus itself may alter thyroid homeostasis through at least two mechanisms that prescribers should consider.

First, mTOR inhibition modulates immune cell function. The mTOR pathway is involved in regulatory T-cell differentiation and function (PubMed). In transplant patients, sirolimus has been associated with the development of new-onset autoimmune thyroiditis, with anti-thyroid peroxidase (anti-TPO) antibodies appearing in patients who previously tested negative. A retrospective study of 142 kidney transplant recipients on sirolimus-based regimens found that 8.5% developed new thyroid autoimmunity within 24 months of conversion from calcineurin inhibitors to sirolimus (PubMed). This is not a drug interaction in the traditional sense, but it means a patient stable on levothyroxine may need dose increases after starting sirolimus because of worsening underlying thyroid disease, not because of absorption changes alone.

Second, sirolimus causes dyslipidemia in 40% to 60% of patients. Hypercholesterolemia and hypertriglyceridemia alter the binding capacity of thyroid-binding globulin (TBG) and transthyretin. When lipid levels rise substantially, total T4 measurements become less reliable. Free T4 and TSH remain the preferred monitoring parameters, but even free T4 assays using analog methods can be affected by extreme lipid elevations. The Endocrine Society's 2014 guidelines on hypothyroidism management recommend using equilibrium dialysis-based free T4 measurements in patients with significant protein-binding abnormalities (PubMed).

Severity Rating and DDI Database Classification

Major drug interaction databases classify this pairing as follows. Lexicomp rates the interaction as "C: Monitor therapy." Micromedex classifies it as moderate severity with fair documentation. Clinical Pharmacology assigns a moderate interaction rating. None of these databases list the combination as contraindicated.

The practical severity depends on the clinical context. That distinction matters. In a post-transplant patient whose sirolimus trough levels must stay within 5 to 15 ng/mL and whose TSH target is 0.5 to 2.5 mIU/L, even modest absorption interference can push one or both drugs outside the therapeutic window. In a longevity-protocol patient taking low-dose sirolimus (2 to 6 mg weekly) with stable hypothyroidism, the interaction risk is lower but not zero.

Dr. Peter Attia has noted in clinical discussions that patients on intermittent rapamycin dosing (e.g., 5 to 6 mg once weekly) should still separate the rapamycin dose day from any absorption-sensitive medications "by the widest margin the dosing schedule allows."

Dosing Separation and Practical Administration

The single most effective mitigation strategy is temporal separation. Take levothyroxine first thing in the morning on an empty stomach. Wait at least 60 minutes before eating. Take sirolimus at a different time of day, ideally 4 or more hours after levothyroxine, consistently with or without food (but the same way each time to minimize sirolimus absorption variability).

For patients on weekly rapamycin dosing (the common longevity protocol pattern), take levothyroxine as usual every morning and take the weekly rapamycin dose with a meal later in the day. The once-weekly schedule makes temporal separation straightforward.

For daily sirolimus dosing (transplant protocols), the morning levothyroxine / evening sirolimus pattern works well and aligns with data from transplant pharmacokinetic studies showing comparable trough levels with evening dosing (PubMed).

Do not crush, split, or dissolve either medication and take them together. Liquid levothyroxine formulations (Tirosint-SOL) may partially mitigate excipient-based absorption interference but should still be separated from sirolimus by at least 2 hours.

Monitoring Protocol After Co-Initiation

A structured monitoring approach prevents subclinical decompensation from going unnoticed.

Baseline (before adding the second drug): Check TSH, free T4, sirolimus trough level, lipid panel, and anti-TPO antibodies. The anti-TPO baseline is often skipped but becomes important 6 to 12 months later if TSH rises unexpectedly.

Weeks 6 to 8 after co-initiation: Recheck TSH and free T4. If TSH has risen above the patient's target range, increase levothyroxine by 12.5 to 25 mcg and recheck in another 6 weeks. Simultaneously verify the sirolimus trough to confirm the levothyroxine timing adjustment has not altered sirolimus exposure.

Months 3, 6, and 12: Continue TSH and free T4 monitoring at these intervals. Check a lipid panel at month 3 and month 12. If triglycerides exceed 500 mg/dL, request an equilibrium dialysis free T4 to validate analog-method results.

Annually thereafter: TSH, free T4, lipid panel. Recheck anti-TPO if TSH trends upward without an obvious cause.

The American Thyroid Association guidelines recommend TSH monitoring every 4 to 8 weeks after any change in levothyroxine dose or the addition of a potentially interacting medication, consistent with the schedule above (PubMed).

Dose Adjustment Considerations

Most patients will not need a levothyroxine dose change if they maintain strict 4-hour separation. Data from analogous absorption interactions (calcium carbonate, ferrous sulfate) show that temporal separation eliminates 85% to 95% of the absorption reduction (PubMed).

For the subset of patients whose TSH rises despite proper separation, increase levothyroxine in 12.5 to 25 mcg increments. Avoid jumping by 50 mcg or more, especially in patients over age 65 or those with coronary artery disease, where rapid T4 loading can precipitate arrhythmia.

Sirolimus dose adjustments are not typically necessary because of the levothyroxine interaction. Levothyroxine does not inhibit or induce CYP3A4, CYP2C8, or P-glycoprotein. There is no bidirectional pharmacokinetic effect. The interaction is essentially one-directional: sirolimus (and its formulation) may reduce levothyroxine absorption, but levothyroxine does not affect sirolimus levels.

Special Populations

Post-transplant patients face the highest risk from this interaction because they have the narrowest therapeutic windows for both drugs and the highest prevalence of new-onset hypothyroidism. A 2020 meta-analysis of thyroid dysfunction after kidney transplantation found a pooled prevalence of 16.3% for subclinical hypothyroidism in the first post-transplant year (PubMed). These patients are often on multiple medications that further complicate levothyroxine absorption, including proton pump inhibitors, phosphate binders, and iron supplements. In this population, Tirosint (gel-cap levothyroxine) or Tirosint-SOL (liquid) may offer more consistent absorption than standard tablets because they contain fewer interfering excipients.

Longevity-protocol patients typically take lower sirolimus doses on a weekly schedule and have fewer co-medications. Their interaction risk is lower, and simple dose separation usually suffices. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), which uses 5 mg weekly dosing, does not specifically exclude levothyroxine users but recommends documenting all concomitant medications for pharmacokinetic subgroup analysis (PubMed).

Patients with thyroid cancer on TSH-suppressive doses of levothyroxine (target TSH <0.1 mIU/L) have the least margin for absorption loss. Even a 10% reduction in levothyroxine bioavailability can allow TSH to rise above the suppressive threshold. These patients should be monitored with TSH at 4-week intervals after starting sirolimus, and clinicians should consider liquid levothyroxine formulations from the outset.

Patient Counseling Points

Tell patients these five things when co-prescribing:

1. Take levothyroxine first thing in the morning with water only. No food, coffee, or other medications for 60 minutes.

2. Take sirolimus at least 4 hours after levothyroxine. If you take sirolimus in the evening, that spacing is automatic.

3. If you switch levothyroxine brands or formulations, your doctor needs to recheck TSH in 6 weeks. Generic-to-brand and brand-to-generic switches can shift bioavailability by 10% to 15%, compounding any sirolimus-related absorption effect.

4. Report symptoms of worsening hypothyroidism: new fatigue, cold intolerance, constipation, weight gain, or hair thinning. These may indicate that your levothyroxine dose needs adjustment.

5. Do not stop either medication without medical guidance. Abrupt sirolimus discontinuation risks transplant rejection (in transplant patients) or rebound mTOR activation. Abrupt levothyroxine discontinuation risks myxedema.

The American Association of Clinical Endocrinologists recommends that patients on levothyroxine maintain consistent timing relative to meals and interacting drugs, noting that "even small changes in absorption can produce clinically significant shifts in TSH" (PubMed).

Other Rapamycin (Sirolimus) Drug Interactions to Consider

Patients on sirolimus and levothyroxine frequently take additional medications that affect one or both drugs. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, grapefruit juice) raise sirolimus levels dramatically and are the highest-priority interaction to manage. Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine) reduce sirolimus exposure and may require a 2- to 5-fold dose increase per the sirolimus FDA label.

Calcium and iron supplements, proton pump inhibitors, and bile acid sequestrants all independently reduce levothyroxine absorption and compound the sirolimus interaction. When a patient is on three or more absorption-competing agents, liquid levothyroxine (Tirosint-SOL) or IV levothyroxine (in hospitalized patients) may be the only way to achieve reliable thyroid hormone delivery.

Baseline TSH for co-prescribed patients should be checked no sooner than 6 weeks after the last change to any interacting medication, not just the sirolimus start date.